Karl-Heinz Klempnauer

List of Publications by Year
in descending order

66 papers	3,243 citations	201674 27 h-index	155660 55 g-index
66 all docs	66 docs citations	66 times ranked	2517 citing authors

#	Article	IF	Citations
1	Viral myb oncogene encodes a sequence-specific DNA-binding activity. Nature, 1988, 335, 835-837.	27.8	606
2	Nucleotide sequence of the retroviral leukemia gene v-myb and its cellular progenitor c-myb: The architecture of a transduced oncogene. Cell, 1982, 31, 453-463.	28.9	568
3	The product of the retroviral transforming gene v-myb is a truncated version of the protein encoded by the cellular oncogene c-myb. Cell, 1983, 33, 345-355.	28.9	229
4	Transformation suppressor protein Pdcd4 interferes with JNK-mediated phosphorylation of c-Jun and recruitment of the coactivator p300 by c-Jun. Oncogene, 2004, 23, 7484-7493.	5.9	133
5	Recruitment of p300 by C/EBPbeta triggers phosphorylation of p300 and modulates coactivator activity. EMBO Journal, 2003, 22, 882-892.	7.8	105
6	Phosphorylation and activation of B-Myb by cyclin Aâ€“Cdk2. Current Biology, 1997, 7, 253-260.	3.9	103
7	The transformation suppressor protein Pdcd4 shuttles between nucleus and cytoplasm and binds RNA. Oncogene, 2003, 22, 4905-4910.	5.9	86
8	Targeting acute myeloid leukemia with a small molecule inhibitor of the Myb/p300 interaction. Blood, 2016, 127, 1173-1182.	1.4	83
9	Tumor Suppressor Protein Pdcd4 Inhibits Translation of p53 mRNA. Journal of Biological Chemistry, 2011, 286, 42855-42862.	3.4	70
10	Activation of the oncogenic transcription factor B-Myb via multisite phosphorylation and prolylcis/transisomerization. Nucleic Acids Research, 2019, 47, 103-121.	14.5	69
11	Regulation of B-Myb activity by cyclin D1. Oncogene, 2000, 19, 298-306.	5.9	61
12	Naphthol AS-E Phosphate Inhibits the Activity of the Transcription Factor Myb by Blocking the Interaction with the KIX Domain of the Coactivator p300. Molecular Cancer Therapeutics, 2015, 14, 1276-1285.	4.1	60
13	Natural sesquiterpene lactones as inhibitors of Myb-dependent gene expression: Structureâ€“activity relationships. European Journal of Medicinal Chemistry, 2013, 63, 313-320.	5.5	51
14	v-Myb Mediates Cooperation of a Cell-Specific Enhancer with the mim-1 Promoter. Molecular and Cellular Biology, 2005, 25, 499-511.	2.3	50
15	The chicken Pdcd4 gene is regulated by v-Myb. Oncogene, 2001, 20, 231-239.	5.9	49
16	Small-Molecule Disruption of the Myb/p300 Cooperation Targets Acute Myeloid Leukemia Cells. Molecular Cancer Therapeutics, 2016, 15, 2905-2915.	4.1	47
17	Characterization of the v-mybDNA binding domain. Nucleic Acids Research, 1990, 18, 1703-1710.	14.5	45
18	Monensin, a novel potent MYB inhibitor, suppresses proliferation of acute myeloid leukemia and adenoid cystic carcinoma cells. Cancer Letters, 2020, 479, 61-70.	7.2	44

#	Article	IF	Citations
19	Targeting the transcription factor Myb by small-molecule inhibitors. Experimental Hematology, 2017, 47, 31-35.	0.4	41
20	C/EBPÎ² Induces Chromatin Opening at a Cell-Type-Specific Enhancer. Molecular and Cellular Biology, 2008, 28, 2102-2112.	2.3	39
21	Identification of cyclin A/Cdk2 phosphorylation sites in B-Myb. FEBS Journal, 2001, 260, 384-391.	0.2	37
22	Helenalin Acetate, a Natural Sesquiterpene Lactone with Anti-inflammatory and Anti-cancer Activity, Disrupts the Cooperation of CCAAT Box/Enhancer-binding Protein Î² (C/EBPÎ²) and Co-activator p300. Journal of Biological Chemistry, 2016, 291, 26098-26108.	3.4	33
23	B-Myb and cyclin D1 mediate heat shock element dependent activation of the human HSP70 promoter. Oncogene, 1997, 14, 1223-1229.	5.9	30
24	The chicken adenosine receptor 2B gene is regulated by v-myb. Oncogene, 1997, 15, 213-221.	5.9	29
25	Structure of the Tandem MA-3 Region of Pdcd4 Protein and Characterization of Its Interactions with eIF4A and eIF4G. Journal of Biological Chemistry, 2011, 286, 17270-17280.	3.4	29
26	Structure of the B-Myb DNA-binding Domain in Solution and Evidence for Multiple Conformations in the Region of Repeat-2 Involved in DNA Binding. Implications for Sequence-Specific DNA Binding by Myb Proteins. FEBS Journal, 1996, 235, 721-735.	0.2	28
27	The cooperation of B-Myb with the coactivator p300 is orchestrated by cyclins A and D1. Oncogene, 2004, 23, 1392-1404.	5.9	27
28	Regulation of the cyclin D1 and cyclin A1 promoters by B-Myb is mediated by Sp1 binding sites. Gene, 2005, 351, 171-180.	2.2	27
29	The natural anti-tumor compound Celastrol targets a Myb-C/EBPÎ²-p300 transcriptional module implicated in myeloid gene expression. PLoS ONE, 2018, 13, e0190934.	2.5	27
30	Association of Tumor Suppressor Protein Pdcd4 With Ribosomes Is Mediated by Protein-Protein and Protein-RNA Interactions. Genes and Cancer, 2010, 1, 293-301.	1.9	26
31	The v-Myb oncoprotein activates C/EBPÎ² expression by stimulating an autoregulatory loop at the C/EBPÎ² promoter. Biochimica Et Biophysica Acta Gene Regulatory Mechanisms, 1999, 1447, 175-184.	2.4	25
32	Solution Structure of the B-Myb DNA-Binding Domain:Â A Possible Role for Conformational Instability of the Protein in DNA Binding and Control of Gene Expressionâ€,â€¡. Biochemistry, 1998, 37, 9619-9629.	2.5	24
33	Disruption of B-myb in DT40 cells reveals novel function for B-Myb in the response to DNA-damage. Oncogene, 2005, 24, 7127-7134.	5.9	22
34	Myb-induced Chromatin Remodeling at a Dual Enhancer/Promoter Element Involves Non-coding RNA Transcription and Is Disrupted by Oncogenic Mutations of v-myb. Journal of Biological Chemistry, 2009, 284, 35314-35324.	3.4	22
35	Targeted disruption of c-myb in the chicken pre B-cell line DT40. Oncogene, 2002, 21, 3076-3081.	5.9	21
36	An evolutionarily conserved interaction of tumor suppressor protein Pdcd4 with the poly(A)-binding protein contributes to translation suppression by Pdcd4. Nucleic Acids Research, 2014, 42, 11107-11118.	14.5	21

#	Article	IF	Citations
37	A novel cell-based screening assay for small-molecule MYB inhibitors identifies podophyllotoxins teniposide and etoposide as inhibitors of MYB activity. Scientific Reports, 2018, 8, 13159.	3.3	20
38	Identification of the myb-inducible promoter of the chicken Pdcd4 gene. Biochimica Et Biophysica Acta Gene Regulatory Mechanisms, 2001, 1520, 99-104.	2.4	18
39	Interaction and Cooperation of the CCAAT-box Enhancer-binding Protein Î² (C/EBPÎ²) with the Homeodomain-interacting Protein Kinase 2 (Hipk2). Journal of Biological Chemistry, 2013, 288, 22257-22269.	3.4	18
40	B-Myb promotes S-phase independently of its sequence-specific DNA binding activity and interacts with polymerase delta-interacting protein 1 (Pdip1). Cell Cycle, 2012, 11, 4047-4058.	2.6	17
41	Withaferin A, a natural compound with anti-tumor activity, is a potent inhibitor of transcription factor C/EBPÎ². Biochimica Et Biophysica Acta - Molecular Cell Research, 2017, 1864, 1349-1358.	4.1	15
42	Proteasome inhibitors suppress MYB oncogenic activity in a p300-dependent manner. Cancer Letters, 2021, 520, 132-142.	7.2	15
43	C/EBPÎ² is a MYB- and p300-cooperating pro-leukemogenic factor and promising drug target in acute myeloid leukemia. Oncogene, 2021, 40, 4746-4758.	5.9	14
44	Myb and Ets transcription factors cooperate at the myb-inducible promoter of the tom-1 gene. Biochimica Et Biophysica Acta Gene Regulatory Mechanisms, 1999, 1446, 243-252.	2.4	13
45	Programmed cell death 4 protein (Pdcd4) and homeodomain-interacting protein kinase 2 (Hipk2) antagonistically control translation of Hipk2 mRNA. Biochimica Et Biophysica Acta - Molecular Cell Research, 2015, 1853, 1564-1573.	4.1	13
46	Transactivation mediated by B-Myb is dependent on TAFII250. Oncogene, 2003, 22, 2932-2941.	5.9	11
47	Interplay with the Mre11-Rad50-Nbs1 complex and phosphorylation by GSK3Î² implicate human B-Myb in DNA-damage signaling. Scientific Reports, 2017, 7, 41663.	3.3	11
48	Characterization of the zinc finger proteins ZMYM2 and ZMYM4 as novel B-MYB binding proteins. Scientific Reports, 2020, 10, 8390.	3.3	10
49	Identification and characterization of the Myb-inducible promoter of the chicken adenosine receptor 2B gene. Oncogene, 2002, 21, 4663-4673.	5.9	9
50	PDCD4 controls the G1/S-phase transition in a telomerase-immortalized epithelial cell line and affects the expression level and translation of multiple mRNAs. Scientific Reports, 2020, 10, 2758.	3.3	9
51	Bcr-TMP, a Novel Nanomolar-Active Compound That Exhibits Both MYB- and Microtubule-Inhibitory Activity. Cancers, 2022, 14, 43.	3.7	9
52	Oncogenic point mutations in the Myb DNA-binding domain alter the DNA-binding properties of Myb at a physiological target gene. Nucleic Acids Research, 2007, 35, 7237-7247.	14.5	8
53	A synthetic covalent ligand of the C/EBPÎ² transactivation domain inhibits acute myeloid leukemia cells. Cancer Letters, 2022, 530, 170-180.	7.2	8
54	Identification of a Myb-responsive enhancer of the chicken C/EBPÎ² gene. Oncogene, 2004, 23, 5807-5814.	5.9	7

#	Article	IF	Citations
55	Interaction of the Transactivation Domain of B-Myb with the TAZ2 Domain of the Coactivator p300: Molecular Features and Properties of the Complex. PLoS ONE, 2012, 7, e52906.	2.5	7
56	Intramolecular interaction of Bâ€MYB is regulated through Serâ€577 phosphorylation. FEBS Letters, 2020, 594, 4266-4279.	2.8	6
57	Expression of protein kinase HIPK2 is subject to a quality control mechanism that acts during translation and requires its kinase activity to prevent degradation of nascent HIPK2. Biochimica Et Biophysica Acta - Molecular Cell Research, 2021, 1868, 118894.	4.1	6
58	Translation, Pdcd4 and eIF4A. Oncoscience, 2015, 2, 731-732.	2.2	6
59	C/EBPÎ² sustains the oncogenic program of AML cells by cooperating with MYB and co-activator p300 in a transcriptional module. Experimental Hematology, 2022, 108, 8-15.	0.4	6
60	Natural Products with Antitumor Potential Targeting the MYB-C/EBPÎ²-p300 Transcription Module. Molecules, 2022, 27, 2077.	3.8	5
61	The CDC37â€HSP90 chaperone complex coâ€translationally degrades the nascent kinaseâ€dead mutant of HIPK2. FEBS Letters, 2021, 595, 1559-1568.	2.8	4
62	Analysis of DNase I-Hypersensitive Sites in the Chromatin of the Chicken C/EBPbeta Gene Reveals Multiplecis-Regulatory Elements. DNA and Cell Biology, 2003, 22, 201-208.	1.9	3
63	Src-Family Protein Kinase Inhibitors Suppress MYB Activity in a p300-Dependent Manner. Cells, 2022, 11, 1162.	4.1	3
64	A dual activation mechanism for Myb-responsive genes in myelomonocytic cells. Blood Cells, Molecules, and Diseases, 2008, 40, 219-226.	1.4	2
65	Characterization of the MYB-inhibitory potential of the Pan-HDAC inhibitor LAQ824. BBA Advances, 2022, 2, 100034.	1.6	2
66	A conserved patch of hydrophobic amino acids modulates Myb activity by mediating proteinâ€“protein interactions. Biochimica Et Biophysica Acta - Gene Regulatory Mechanisms, 2016, 1859, 914-921.	1.9	1